Pharmaceutical product 6
Storing ophthalmic preparations with halogenated isoquinoline derivatives in polyolefin resin containers addresses the issue of discoloration during high-temperature storage, maintaining formulation stability and efficacy.
Patent Information
- Application Number
- JP2024139403
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-09-25
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Ophthalmic preparations containing halogenated isoquinoline derivatives like ripasudil undergo discoloration when stored in certain materials at high temperatures for extended periods.
Storing the aqueous composition containing halogenated isoquinoline derivatives in a polyolefin resin container, such as polyethylene or polypropylene, to suppress discoloration during high-temperature storage.
The use of polyolefin resin containers effectively prevents discoloration of the aqueous composition, ensuring stability and maintaining the pharmaceutical efficacy of the formulation.
Smart Images

Figure 2024160370000001 
Figure 2024160370000002 
Figure 2024160370000003
Abstract
Description
[Technical field]
[0001] The present invention relates to pharmaceutical preparations and the like. [Background technology]
[0002] The structural formula:
[0003] [ka]
[0004] Ripasudil (chemical name: 4-fluoro-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline) represented by the following structural formula:
[0005] [ka]
[0006] Halogenated isoquinoline derivatives such as 4-bromo-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline represented by the formula (I) have pharmacological effects such as Rho kinase inhibitory action (e.g., Patent Documents 1 and 2) and are known to be useful for the prevention and treatment of eye diseases. Specifically, it has been reported that they are useful for the prevention or treatment of ocular hypertension, glaucoma, and the like (e.g., Patent Document 3), or for the prevention or treatment of ocular fundus diseases such as age-related macular degeneration (e.g., Patent Document 4).
[0007] Therefore, it would be extremely useful to establish a technique for stably formulating these halogenated isoquinoline derivatives into, for example, ophthalmic preparations. [Prior art documents] [Patent documents]
[0008] [Patent Document 1] Patent No. 4212149 [Patent Document 2] International Publication No. 2006 / 115244 Brochure [Patent Document 3] International Publication No. 2006 / 068208 Brochure [Patent Document 4] Patent No. 5557408 Summary of the Invention [Problem to be solved by the invention]
[0009] Ophthalmic preparations and the like are usually compositions containing water (aqueous compositions), and need to be stored in a container to prevent the contents from dissipating and the inclusion of impurities from the outside air. Therefore, when formulating Ripasudil, a halogenated isoquinoline derivative, as an ophthalmic preparation and the like, the present inventors investigated the material of the container for storing the aqueous composition. However, it was found that when an aqueous composition containing Ripasudil is stored in a container made of a specific material, a problem occurs in that the aqueous composition discolors due to long-term storage at high temperatures. Therefore, an object of the present invention is to provide a technique for suppressing discoloration of an aqueous composition containing a halogenated isoquinoline derivative during storage at high temperatures. [Means for solving the problem]
[0010] Therefore, the present inventors conducted intensive research to solve the above-mentioned problems and discovered that when an aqueous composition containing a halogenated isoquinoline derivative such as Ripasudil is stored in a container, discoloration can be specifically suppressed even after long-term storage at high temperatures when the container is made of a polyolefin-based resin, and thus completed the present invention.
[0011] That is, the present invention provides a compound represented by the following general formula (1):
[0012] [ka]
[0013] [In the formula, X represents a halogen atom.] or a salt thereof, or a solvate thereof, is contained in a polyolefin resin container. The present invention also provides a method for suppressing discoloration of an aqueous composition, the method comprising the step of placing an aqueous composition containing a compound represented by general formula (1) or a salt thereof, or a solvate of either of them in a polyolefin resin container. Effect of the Invention
[0014] According to the present invention, discoloration of an aqueous composition containing a halogenated isoquinoline derivative such as Ripasudil during high-temperature storage can be suppressed. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] The present specification discloses, for example, the following aspects of the invention, although the invention is in no way limited thereto. [1] The following general formula (1)
[0016] [ka]
[0017] [In the formula, X represents a halogen atom.] or a salt thereof, or a solvate thereof, is contained in a polyolefin resin container. [2] The pharmaceutical formulation according to [1], wherein the compound represented by the general formula (1) is ripasudil. [3] The pharmaceutical formulation according to [1] or [2], wherein the polyolefin resin is polyethylene or polypropylene. [4] The pharmaceutical preparation according to any one of [1] to [3], wherein the polyolefin resin container is an eye drop container. [5] A method for suppressing discoloration of an aqueous composition, comprising the step of placing an aqueous composition containing the compound represented by general formula (1) or a salt thereof, or a solvate of either of them in a polyolefin-based resin container. [6] The method according to [5], wherein the compound represented by the general formula (1) is ripasudil. [7] The method according to [5] or [6], wherein the polyolefin resin is polyethylene or polypropylene. [8] The method according to any one of [5] to [7], wherein the polyolefin resin container is an eye drop container.
[0018] [9] The pharmaceutical formulation according to any one of [1] to [4], wherein the aqueous composition further contains one or more selected from the group consisting of α1 receptor blockers, α2 receptor agonists, β-blockers, carbonic anhydrase inhibitors, prostaglandin F2α derivatives, sympathomimetics, parasympathomimetics, calcium antagonists, and cholinesterase inhibitors.
[10] The pharmaceutical formulation according to any one of [1] to [4], wherein the aqueous composition further contains one or more selected from the group consisting of latanoprost, nipradilol, dorzolamide, brinzolamide, and timolol, and salts thereof.
[11] The method according to any one of [5] to [8], wherein the aqueous composition further contains one or more selected from the group consisting of α1 receptor blockers, α2 receptor agonists, β-blockers, carbonic anhydrase inhibitors, prostaglandin F2α derivatives, sympathomimetics, parasympathomimetics, calcium antagonists and cholinesterase inhibitors.
[12] The method according to any one of [5] to [8], wherein the aqueous composition further contains one or more selected from the group consisting of latanoprost, nipradilol, dorzolamide, brinzolamide, and timolol, and salts thereof.
[0019] In the general formula (1), examples of the halogen atom include a fluorine atom, a chlorine atom, a bromine atom, etc. In the general formula (1), examples of the halogen atom include a fluorine atom and a bromine atom, and a fluorine atom is particularly preferred. In addition, in the general formula (1), the carbon atom constituting the homopiperazine ring substituted with a methyl group is an asymmetric carbon. Therefore, stereoisomerism occurs, but the compound represented by the general formula (1) includes any stereoisomer, and may be a single stereoisomer or a mixture of various stereoisomers in any ratio. As the compound represented by the general formula (1), a compound having an absolute configuration of S configuration is preferable.
[0020] The salt of the compound represented by the general formula (1) is not particularly limited as long as it is a pharma- ceutically acceptable salt, and specific examples thereof include inorganic acid salts such as hydrochloride, sulfate, nitrate, hydrofluoride, and hydrobromide; and organic acid salts such as acetate, tartrate, lactate, citrate, fumarate, maleate, succinate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, naphthalenesulfonate, and camphorsulfonate, and hydrochloride is preferred. Furthermore, the compound represented by the general formula (1) or a salt thereof may be a solvate such as a hydrate or an alcohol solvate, and is preferably a hydrate.
[0021] Specific examples of the compound represented by the general formula (1) or a salt thereof, or a solvate thereof include Ripasudil (chemical name: 4-fluoro-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline) or its salts or solvates; 4-bromo-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline or a salt thereof, or a solvate thereof; etc.
[0022] The compound represented by the general formula (1) or a salt thereof, or a solvate thereof is preferably Ripasudil, a salt thereof, or a solvate thereof, 4-bromo-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline, a salt thereof, or a solvate thereof, more preferably Ripasudil, a salt thereof, or a solvate thereof, and even more preferably Ripasudil, its hydrochloride, or a hydrate thereof, and has the following structural formula:
[0023] [ka]
[0024] Ripasudil hydrochloride hydrate (Ripasudil monohydrochloride dihydrate) represented by the following formula is particularly preferred.
[0025] The compound represented by the general formula (1) or its salt or solvate thereof is known and can be produced by known methods. Specifically, for example, Ripasudil or its salt or solvate thereof can be produced by the methods described in WO 1999 / 020620 and WO 2006 / 057397. In addition, 4-bromo-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline or its salt or solvate thereof can be produced by the methods described in WO 2006 / 115244.
[0026] The content of the compound represented by the general formula (1) or its salt or solvate thereof in the aqueous composition is not particularly limited, and may be appropriately determined depending on the disease to be treated, the sex, age, symptoms, etc. of the patient, but from the viewpoint of obtaining an excellent pharmacological action, it is preferable to contain 0.01 to 10 w / v% of the compound represented by the general formula (1) in terms of the free form, more preferably 0.02 to 8 w / v%, and particularly preferably 0.04 to 6 w / v% relative to the total volume of the aqueous composition. Among them, when using Ripasudil as the compound represented by the general formula (1), from the viewpoint of obtaining an excellent pharmacological action, it is preferable to contain Ripasudil or its salt or solvate thereof in terms of the free form, based on the total volume of the aqueous composition, at 0.05 to 5 w / v%, more preferably 0.1 to 3 w / v%, and particularly preferably 0.1 to 2 w / v%.
[0027] In the present specification, the term "aqueous composition" refers to a composition containing at least water, and its properties include liquid (solution or suspension) and semi-solid (ointment). The water in the composition may be, for example, purified water, water for injection, sterilized purified water, etc. The water content in the aqueous composition is not particularly limited, but is preferably 5% by mass or more, more preferably 20% by mass or more, even more preferably 50% by mass or more, even more preferably 90% by mass or more, and particularly preferably 90 to 99.8% by mass.
[0028] The aqueous composition can be made into various dosage forms, for example, according to known methods described in the General Provisions for Preparations of the 16th Edition of the Japanese Pharmacopoeia, etc. The dosage form is not particularly limited as long as it can be accommodated in a container described later, and examples thereof include injections, inhalation solutions, eye drops, eye ointments, ear drops, nasal drops, enemas, external solutions, sprays, ointments, gels, oral solutions, syrups, etc. From the viewpoint of advantageously utilizing the pharmacological action of the compound represented by general formula (1), the dosage form is preferably an agent for eye diseases, specifically eye drops and eye ointments, and more preferably eye drops.
[0029] In addition to the above, the aqueous composition may contain additives used in pharmaceuticals, quasi-drugs, etc., depending on the dosage form. Examples of such additives include inorganic salts, isotonicity agents, chelating agents, stabilizers, pH regulators, preservatives, antioxidants, thickening agents, surfactants, solubilizers, suspending agents, refreshing agents, dispersants, preservatives, oily bases, emulsion bases, water-soluble bases, etc. Specific examples of such additives include ascorbic acid, potassium aspartate, sodium hydrogen sulfite, alginic acid, sodium benzoate, benzyl benzoate, epsilon-aminocaproic acid, fennel oil, ethanol, ethylene-vinyl acetate copolymer, sodium edetate, tetrasodium edetate, potassium chloride, calcium chloride hydrate, sodium chloride, magnesium chloride, hydrochloric acid, alkyldiaminoethylglycine hydrochloride solution, carboxyvinyl polymer, dry sodium sulfite, dry sodium carbonate, d-camphor, dl-camphor, Xylitol, citric acid hydrate, sodium citrate hydrate, glycerin, gluconic acid, L-glutamic acid, sodium L-glutamate, creatinine, chlorhexidine gluconate solution, chlorobutanol, crystalline sodium dihydrogen phosphate, geraniol, sodium chondroitin sulfate, acetic acid, potassium acetate, sodium acetate hydrate, titanium dioxide, gellan gum, dibutyl hydroxytoluene, potassium bromide, benzododecyl bromide, tartaric acid, sodium hydroxide, polyoxyl 45 stearate, purified lanolin, D-sorbitol, sorbitol Solution, sorbic acid, potassium sorbate, taurine, sodium bicarbonate, sodium carbonate hydrate, sodium thiosulfate hydrate, thimerosal, tyloxapol, sodium dehydroacetate, trometamol, concentrated glycerin, concentrated mixed tocopherols, white petrolatum, peppermint water, peppermint oil, concentrated benzalkonium chloride solution 50, ethyl parahydroxybenzoate, butyl parahydroxybenzoate, propyl parahydroxybenzoate, methyl parahydroxybenzoate, sodium hyaluronate, human serum albumin, hydroxyethyl cellulose, hydroxypropyl cellulose, hyaluronic acid Promellose, glacial acetic acid, sodium pyrosulfite, phenylethyl alcohol, glucose, propylene glycol, bergamot oil, benzalkonium chloride, benzalkonium chloride solution, benzyl alcohol, benzethonium chloride, benzethonium chloride solution, borax, boric acid, povidone, polyoxyethylene (200), polyoxypropylene glycol (70), sodium polystyrene sulfonate, polysorbate 80, polyoxyethylene hydrogenated castor oil 60, polyvinyl alcohol (partially saponified), d-borneol, macrogol 4000,Examples of such additives include macrogol 6000, D-mannitol, anhydrous citric acid, anhydrous sodium monohydrogen phosphate, anhydrous sodium dihydrogen phosphate, methanesulfonic acid, methylcellulose, l-menthol, monoethanolamine, aluminum monostearate, polyethylene glycol monostearate, eucalyptus oil, potassium iodide, sulfuric acid, oxyquinoline sulfate, liquid paraffin, ryuuno, phosphoric acid, sodium hydrogen phosphate hydrate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium dihydrogen phosphate monohydrate, malic acid, and petrolatum.
[0030] Examples of preferred additives include potassium chloride, calcium chloride hydrate, sodium chloride, magnesium chloride, glycerin, acetic acid, potassium acetate, sodium acetate hydrate, tartaric acid, sodium hydroxide, sodium bicarbonate, sodium carbonate hydrate, concentrated glycerin, hydroxyethyl cellulose, hydroxypropyl cellulose, hypromellose, borax, boric acid, povidone, polysorbate 80, polyoxyethylene hydrogenated castor oil, polyethylene glycol monostearate, polyvinyl alcohol (partially saponified), macrogol 4000, macrogol 6000, anhydrous citric acid, anhydrous sodium monohydrogen phosphate, anhydrous sodium dihydrogen phosphate, methylcellulose, monoethanolamine, phosphoric acid, sodium hydrogen phosphate hydrate, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium dihydrogen phosphate monohydrate, sodium hyaluronate, glucose, and l-menthol.
[0031] The aqueous composition may further contain other medicinal ingredients in addition to those mentioned above, depending on the disease to which it is applied, etc. Examples of such medicinal ingredients include α1 receptor blockers including bunazosin, such as bunazosin hydrochloride, or a salt thereof, or a solvate thereof; brimonidine, such as brimonidine tartrate, or a salt thereof, or a solvate thereof; α2 receptor agonists including apraclonidine, a salt thereof, or a solvate thereof; carteolol, such as carteolol hydrochloride, or a salt thereof, or a solvate thereof; nipradilol, or a salt thereof, or a solvate thereof; timolol, such as timolol maleate, or a salt thereof, or a solvate thereof; beta-blockers including benzodiazepines, benzotriazoles, benzocaine, benzotriazoles, benzoyl peroxides, benzotriazoles, benzoyl peroxides, benzoyl peroxides; betaxolol or its salts or solvates such as betaxolol hydrochloride, levobunolol or its salts or solvates such as levobunolol hydrochloride, befunolol or its salts or solvates, metipranolol or its salts or solvates; dorzolamide or its salts or solvates such as dorzolamide hydrochloride, brinzolamide or its salts or solvates, acetazolamide or its salts or solvates, dichlorphenamide or or a salt thereof or a solvate thereof, carbonic anhydrase inhibitors including methazolamide or a salt thereof or a solvate thereof; isopropyl unoprostone or a salt thereof or a solvate thereof, tafluprost or a salt thereof or a solvate thereof, travoprost or a salt thereof or a solvate thereof, bimatoprost or a salt thereof or a solvate thereof, latanoprost or a salt thereof or a solvate thereof, cloprostenol or a salt thereof or a solvate thereof, and fluprostenol or a salt thereof or a solvate thereof. prostaglandin F2α derivatives including those mentioned above; sympathomimetics including dipivefrin or its salts or solvates thereof, such as dipivefrin hydrochloride, epinephrine, epinephrine borate, epinephrine hydrochloride, or its salts or solvates thereof; parasympathomimetics including distigmine bromide or its salts or solvates thereof, pilocarpine or its salts or solvates thereof, such as pilocarpine, pilocarpine hydrochloride, pilocarpine nitrate, or carbachol or its salts or solvates thereof;Calcium antagonists including lomerizine, such as lomerizine hydrochloride, or a salt thereof or a solvate thereof; cholinesterase inhibitors including demecarium, a salt thereof or a solvate thereof, echothiophate, a salt thereof or a solvate thereof, and physostigmine, a salt thereof or a solvate thereof, and the like, and one or more of these may be combined; The other active ingredient is preferably one or more selected from the group consisting of latanoprost, nipradilol, dorzolamide, brinzolamide, timolol, and salts thereof.
[0032] The pH of the aqueous composition is not particularly limited, but is preferably 4 to 9, more preferably 4.5 to 8, and particularly preferably 5 to 7. The osmotic pressure ratio to physiological saline is not particularly limited, but is preferably 0.6 to 3, and particularly preferably 0.6 to 2.
[0033] In the present specification, the term "container" refers to a package that directly contains the aqueous composition. The term "container" is a concept that encompasses any of "sealed containers," "airtight containers," and "sealed containers" defined in the General Rules of the Japanese Pharmacopoeia, 16th Edition.
[0034] The shape of the container is not particularly limited as long as it can accommodate the aqueous composition, and may be appropriately selected and set depending on the dosage form, the use of the pharmaceutical preparation, etc. Specific examples of such container shapes include containers for injections, containers for inhalants, containers for sprays, bottle-shaped containers, tube-shaped containers, containers for eye drops, containers for nasal drops, containers for ear drops, bag containers, etc.
[0035] In this specification, the term "polyolefin resin container" refers to a container in which at least the portion of the container that comes into contact with the aqueous composition is made of a polyolefin resin. Therefore, for example, a container in which a polyolefin layer is provided as an inner layer that comes into contact with the aqueous composition and a resin of another material is laminated on the outside also falls under the category of "polyolefin resin container". Here, the polyolefin resin is not particularly limited, and may be a polymer (homopolymer) of a single type of monomer or a copolymer (copolymer) of multiple types of monomers. In addition, in the case of a copolymer, the polymerization mode is not particularly limited, and may be random polymerization or block polymerization. Furthermore, the stereoregularity (tacticity) is not particularly limited. Specific examples of such polyolefin resins include polyethylene (more specifically, for example, low-density polyethylene (including linear low-density polyethylene), high-density polyethylene, medium-density polyethylene, etc.), polypropylene, cyclic polyolefins, poly(4-methylpentene), polytetrafluoroethylene, ethylene-propylene copolymers, ethylene-α-olefin copolymers, ethylene-acrylic acid copolymers, ethylene-methacrylic acid copolymers, ethylene-vinyl acetate copolymers, ethylene-ethyl acrylate copolymers, etc., and one or more of these can be used in combination. As the polyolefin resins, from the viewpoint of suppressing discoloration, polyethylene, polypropylene, and cyclic polyolefins are preferred, polyethylene and polypropylene are more preferred, and polypropylene is particularly preferred. In this specification, "made of polyolefin-based resin" means that at least a portion of the material contains polyolefin-based resin; for example, a mixture of two or more resins, that is, a polyolefin-based resin and another resin (polymer alloy), is also included in "made of polyolefin-based resin".
[0036] It is preferable to further knead a substance that blocks the transmission of ultraviolet light, such as an ultraviolet absorbing agent or an ultraviolet scattering agent, into the polyolefin resin container. This improves the stability of the compound represented by general formula (1) against light. Specific examples of such substances include titanium oxide as an ultraviolet scattering agent;Examples include zinc oxide. Examples of ultraviolet absorbers include 2-(2H-benzotriazol-2-yl)-p-cresol (e.g., Tinuvin P, manufactured by BASF), 2-(2H-benzotriazol-2-yl)-4,6-bis(1-methyl-1-phenylethyl)phenol (e.g., Tinuvin 234, manufactured by BASF), 2-(3,5-di-t-butyl-2-hydroxyphenyl)benzotriazole (e.g., Tinuvin 320, manufactured by BASF), 2-[5-chloro(2H)-benzotriazol-2-yl]-4-methyl-6-(tert-butyl)phenol (e.g., Tinuvin 326, manufactured by BASF), 2-(3,5-di-t-butyl-2-hydroxyphenyl)-5-chlorobenzotriazole (e.g., Tinuvin 327, manufactured by BASF), 2-(2H-benzotriazol-2-yl)-4,6-di-tert-pentylphenol (e.g., Tinuvin PA328: BASF), 2-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol (e.g., Tinuvin 329: BASF), 2,2'-methylenebis[6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol (e.g., Tinuvin 360: BASF), reaction product of methyl 3-(3-(2H-benzotriazol-2-yl)-5-tert-butyl-4-hydroxyphenyl)propionate with polyethylene glycol 300 (e.g., Tinuvin 213: BASF), 2-(2H-benzotriazol-2-yl)-6-dodecyl-4-methylphenol (e.g., Tinuvin 571: BASF), benzotriazole-based ultraviolet absorbers such as 2-(2'-hydroxy-3',5'-di-t-amylphenyl)benzotriazole, 2-[2'-hydroxy-3'-(3'',4'',5'',6''-tetrahydrophthalimidomethyl)-5'-methylphenyl]benzotriazole, and 2,2'-methylenebis[4-(1,1,3,3-tetramethylbutyl)-6-(2H-benzotriazol-2-yl)phenol];Cyanoacrylate-based UV absorbers such as 2,2-bis{[2-cyano-3,3-diphenylacryloyloxy]methyl}propane-1,3-diyl=bis(2-cyano-3,3-diphenylacrylate) (e.g., Uvinul 3030 FF: BASF), ethyl 2-cyano-3,3-diphenylacrylate (e.g., Uvinul 3035: BASF), and 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (e.g., Uvinul 3039: BASF); triazine-based UV absorbers such as 2-(4,6-diphenyl-1,3,5-triazin-2-yl)-5-[(hexyl)oxy]-phenol (e.g., Tinuvin 1577 ED: BASF); octabenzone (e.g., Chimassorb 81:BASF), 2,2'-dihydroxy-4,4'-dimethoxybenzophenone (e.g., Uvinul 3049:BASF), 2,2'-4,4'-tetrahydrobenzophenone (e.g., Uvinul 3050:BASF), oxybenzone, hydroxymethoxybenzophenone sulfonic acid, hydroxymethoxybenzophenone sodium sulfonate, dihydroxydimethoxybenzophenone, dihydroxydimethoxybenzophenone sodium disulfonate, dihydroxybenzophenone, tetrahydroxybenzophenone and other benzophenone-based ultraviolet absorbers; methyl diisopropylcinnamate, cinoxate, glyceryl di-p-methoxycinnamate mono-2-ethylhexanoate, isopropyl p-methoxycinnamate / diisopropylcinnamate mixture, 2-ethylhexyl p-methoxycinnamate, benzyl cinnamate cinnamic acid-based UV absorbers such as para-aminobenzoic acid, ethyl para-aminobenzoate, glyceryl para-aminobenzoate, amyl para-dimethylaminobenzoate, 2-ethylhexyl para-dimethylaminobenzoate, and ethyl 4-[N,N-di(2-hydroxypropyl)amino]benzoate; salicylic acid-based UV absorbers such as ethylene glycol salicylate, octyl salicylate, dipropylene glycol salicylate, phenyl salicylate, homomenthyl salicylate, and methyl salicylate; guaiazulene; 2-ethylhexyl dimethoxybenzylidene dioxoimidazolidinepropionate;2,4,6-tris[4-(2-ethylhexyloxycarbonyl)anilino]1,3,5-triazine; parahydroxyanisole; 4-tert-butyl-4'-methoxydibenzoylmethane; phenylbenzimidazole sulfonic acid; 2-(4-diethylamino-2-hydroxybenzoyl)-hexyl benzoate;
[0037] When a substance that blocks ultraviolet light transmission is kneaded into the container, the mixing ratio varies depending on the type of substance, etc., but may be, for example, about 0.001 to 50 mass %, preferably 0.002 to 25 mass %, and particularly preferably 0.01 to 10 mass % in the container.
[0038] The inside of the container is preferably visible (observable) with the naked eye. If the inside is visible, there are advantages such as enabling inspection for the presence or absence of foreign matter in the manufacturing process of the pharmaceutical preparation, and enabling users of the pharmaceutical preparation to check the remaining amount of the contents (aqueous composition). Here, visibility is sufficient as long as at least a part of the container surface is ensured (for example, even if the side of an eye drop container is obscured by a shrink film or the like, it can be said to be visible as long as the bottom surface is visible). If the inside is visible from a part of the container surface, this allows the aqueous composition in the container to be confirmed.
[0039] The means for storing the aqueous composition in the container is not particularly limited, and the aqueous composition may be filled in a conventional manner according to the shape of the container.
[0040] The indications for the pharmaceutical preparation are not particularly limited, and may be appropriately selected depending on the pharmacological action of the compound represented by the general formula (1) above. Specifically, for example, the compound represented by formula (1) can be used as a preventive or therapeutic agent for ocular hypertension or glaucoma based on its Rho kinase inhibitory activity and intraocular pressure reducing activity. More specific examples of glaucoma include primary open-angle glaucoma, normal tension glaucoma, aqueous humor hyperproduction glaucoma, acute angle-closure glaucoma, chronic angle-closure glaucoma, plateau iris syndrome, mixed glaucoma, steroid-induced glaucoma, lenticular capsular glaucoma, pigmentary glaucoma, amyloid glaucoma, neovascular glaucoma, and malignant glaucoma.
[0041] As disclosed in Japanese Patent No. 5557408, ocular fundus diseases (lesions mainly occurring in the retina and / or choroid. Specific examples thereof include fundus changes due to hypertension and arteriosclerosis, retinal vein occlusions such as central retinal artery occlusion, central retinal vein occlusion, and branch retinal vein occlusion, congenital retinal vascular anomalies such as diabetic retinopathy, diabetic macular edema, diabetic macular edema, Eales disease, and Coats disease, von Hippel disease, pulseless disease, macular diseases (central serous chorioretinopathy, cystoid macular edema, age-related macular degeneration, macular hole, myopic macular atrophy, etc.), and other diseases. degeneration), vitreoretinal interface macular degeneration, drug-induced macular degeneration, hereditary macular degeneration, etc.), retinal detachment (rhegmatogenous, tractional, exudative, etc.), retinitis pigmentosa, retinopathy of prematurity, etc.), more preferably as an agent for the prevention or treatment of diabetic retinopathy, diabetic macular edema, or age-related macular degeneration. EXAMPLES
[0042] The present invention will now be described in further detail with reference to examples, but the present invention is not limited to these in any way. In the following test examples, Ripasudil monohydrochloride dihydrate can be prepared, for example, by the method described in WO 2006 / 057397.
[0043] [Test Example 1] Preservation test Part 1 An aqueous composition having the formulation shown in Table 1 was prepared by a conventional method, and then placed in a container made of polyethylene (PE), polypropylene (PP), or polyvinyl chloride (PVC) to prepare a pharmaceutical preparation. Each of the obtained pharmaceutical preparations was stored at 60°C for 3 months, and the color difference (ΔYI) before and after storage was measured using a color difference meter (spectrophotometer CM-700d: Konica Minolta Sensing Co., Ltd.). ΔYI values of 5 or more were evaluated as ×, and those less than 5 were evaluated as ○. The results are shown in Table 2.
[0044] [Table 1]
[0045] [Table 2]
[0046] As shown in the results in Table 2, when an aqueous composition containing Ripasudil was placed in a container made of a polyolefin resin such as polyethylene (PE) or polypropylene (PP), the ΔYI value was kept low even when stored at high temperatures for long periods of time, whereas when it was placed in a container made of polyvinyl chloride (PVC), the ΔYI value was high.
[0047] [Test Example 2] Preservation test Part 2 An aqueous composition having the formulation shown in Table 3 was prepared by a conventional method, and then placed in a polyethylene (PE) or polypropylene (PP) container to prepare a pharmaceutical preparation. Each of the obtained pharmaceutical preparations was stored at 60°C for 3 months, and the color difference (ΔYI) before and after storage was measured using a color difference meter (spectrophotometer CM-700d: Konica Minolta Sensing Co., Ltd.). ΔYI values of 5 or more were evaluated as ×, and those less than 5 were evaluated as ○. The results are shown in Table 4.
[0048] [Table 3]
[0049] [Table 4]
[0050] As shown in the results in Table 4, even when the formulation of the aqueous composition was changed, the ΔYI value was kept low when the composition was stored in a polyolefin resin container such as polyethylene (PE) or polypropylene (PP) at high temperatures for a long period of time.
[0051] From the results of the above test examples 1 and 2, it was revealed that when an aqueous composition containing a compound represented by general formula (1) including Ripasudil or a salt thereof, or a solvate thereof is placed in a polyolefin resin container, discoloration is relatively unlikely to occur even when stored at high temperatures for long periods of time, and the storage stability is excellent.
[0052] [Manufacturing Examples 1-27] Aqueous compositions containing the components and amounts (amounts (g) per 100 mL of the aqueous composition) shown in Tables 5 to 7 are prepared by a conventional method, and then placed in a polyethylene eye drop container to produce the pharmaceutical preparations of Preparation Examples 1 to 27.
[0053] [Table 5]
[0054] [Table 6]
[0055] [Table 7]
[0056] [Examples 28-54] The pharmaceutical preparations of Preparation Examples 28 to 54 can be produced by using polypropylene eye drop containers instead of polyethylene containers in Preparation Examples 1 to 27.
[0057] [Examples 55-81] In Production Examples 1 to 27, the pharmaceutical preparations of Production Examples 55 to 81 can be produced by using an eye drop container made of cyclic polyolefin (COP) instead of polyethylene.
[0058] [Manufacturing Examples 82-162] In Preparation Examples 1 to 81, the same amount of 4-bromo-5-[[(2S)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline is used instead of Ripasudil monohydrochloride dihydrate, and the pharmaceutical preparations of Preparation Examples 82 to 162 can be produced by a conventional method. [Industrial Applicability]
[0059] INDUSTRIAL APPLICABILITY According to the present invention, a pharmaceutical preparation having excellent storage stability can be provided, which can be suitably used in the pharmaceutical industry and the like.
Claims
[Claim 1] The invention described in the application.
Citation Information
Patent Citations
Veneer reinforcing treating device for veneer lathe
JP1980057408A
medicine
JP4212149B2
Preventive or therapeutic agent for glaucoma
WO2006068208A1
4-bromoisoquinoline derivative and pharmaceutical preparation comprising the same
WO2006115244A1
